State of New Jersey Common Pension Fund D Sells 723 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

State of New Jersey Common Pension Fund D reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,939 shares of the specialty pharmaceutical company’s stock after selling 723 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Jazz Pharmaceuticals were worth $2,825,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Bleakley Financial Group LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at about $227,000. Raymond James & Associates grew its position in shares of Jazz Pharmaceuticals by 13.3% during the 3rd quarter. Raymond James & Associates now owns 53,611 shares of the specialty pharmaceutical company’s stock worth $5,973,000 after buying an additional 6,293 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Jazz Pharmaceuticals by 9.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 19,629 shares of the specialty pharmaceutical company’s stock worth $2,187,000 after buying an additional 1,616 shares during the period. Signaturefd LLC grew its holdings in Jazz Pharmaceuticals by 273.4% during the third quarter. Signaturefd LLC now owns 1,516 shares of the specialty pharmaceutical company’s stock valued at $169,000 after purchasing an additional 1,110 shares during the period. Finally, Private Advisor Group LLC grew its holdings in Jazz Pharmaceuticals by 238.6% during the third quarter. Private Advisor Group LLC now owns 7,716 shares of the specialty pharmaceutical company’s stock valued at $860,000 after purchasing an additional 5,437 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $136.84 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm’s fifty day moving average price is $124.59 and its two-hundred day moving average price is $117.82. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $138.27. The firm has a market capitalization of $8.27 billion, a P/E ratio of 19.27, a price-to-earnings-growth ratio of 1.03 and a beta of 0.56.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 5,053 shares of company stock valued at $617,442. 4.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of analyst reports. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Royal Bank of Canada restated an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $180.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.